Cyber Week Sale! 20% OFF Use Code CM20 *
ON SALE! For a limited time. Add to cart to see automatic coupon. We have the best price and service on the internet.
Elura is a first-in-class ghrelin receptor agonist, providing a novel mechanism of action to address weight loss in cats with CKD. It binds to receptors in the hypothalamus to stimulate appetite and in the pituitary to stimulate secretion of growth hormone (GH). Weight gain in cats taking Elura is thought to be due to a combination of increased food intake and metabolic changes.
Elura is indicated for the management of weight loss in cats with chronic kidney disease.
Administer ELURA orally at a dose of 2 mg/kg (0.9 mg/lb) or 0.1 mL/kg (0.045 mL/lb) body weight once daily.
If the cat is routinely fed meals, offer food 30 minutes after administering the dose.If the cat vomits within 15 minutes or only receives a partial dose, then the dose may be re-administered.
The clinical effects of Elura are thought to be due to a combination of increased food intake and metabolic changes resulting in weight gain
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
ELURA should not be used in cats that have a hypersensitivity to capromorelin.
Not for use in humans. Keep this and all medications out of reach of children and pets. Consult a physician in case of accidental ingestion by humans.
For oral use in cats only.
Do not use in cats with hypersomatotropism (acromegaly). ELURA may increase serum glucose for several hours after dosing (see Animal Safety and Clinical Pharmacology). Use in cats with current or historical diabetes mellitus has not been evaluated and use may not be appropriate.
Use with caution in cats that may have cardiac disease or severe dehydration. ELURA causes transient decreases in heart rate and blood pressure up to 4 hours following dose administration.
Some cats may exhibit clinical signs of bradycardia or hypotension following administration of ELURA. (See Adverse Reactions and Animal Safety).
Use with caution in cats with hepatic dysfunction. Capromorelin is metabolized in the liver in humans and dogs and similar metabolism is expected in the cat. The safe use of ELURA has not been evaluated in cats younger than 5 months old.
The safe use of ELURA has not been evaluated in cats that are pregnant, lactating, or intended for breeding.
Owners should be advised that ELURA mimics the action of a naturally-occurring hormone called ghrelin. Ghrelin influences many systems in the body. ELURA may also affect these systems. Owners should monitor for changes in: thirst or water intake; lethargy or weakness; digestive issues (vomiting, diarrhea, drooling, decreased appetite); or behaviors.
For oral use in cats only. Do not use in cats that have a hypersensitivity to capromorelin, or in cats with hypersomatotropism (acromegaly). Elura may increase serum glucose for several hours after dosing; use in cats with current or historical diabetes mellitus has not been evaluated and may not be appropriate. Use with caution in cats that may have cardiac disease, severe dehydration, or hepatic dysfunction. Elura has not been evaluated in cats younger than 5 months of age, or in breeding, pregnant or lactating cats. The most common adverse reactions included vomiting, hypersalivation, inappetence, behavior change and lethargy. Please see Elura product label for full Prescribing Information.
Store at or below 86°F (30°C)